HCPs Anticipate Disruption of Oral T2D Landscape by Division
ncarol.com/10211391

RESEARCH TRIANGLE PARK, N.C. - ncarol.com -- A variety of factors are considered when healthcare providers (HCPs) speak upon which type 2 diabetes treatments in the clinical pipeline may be more disruptive and why. According to newly published data by market research from Vivisum Partners, LLC., new arrivals are likely to take some pieces of the current share of oral treatments on market, but it may be enough to cause some dents in multiple treatments due to viable alternatives.

The current market holds a lot of excitement for the oral type 2 diabetes pipeline for drugs that are just as comparable in tolerability, but may differ on other clinical attributes, such as dosing. The most potential risk for a more established treatment will be pipeline products gaining more access.

For example, according to Oral T2D Clinical Pipeline, many HCPs expect oral Insulin's efficacy to be slightly or much better than current oral T2D treatments. In dosing, oral Insulin is believed to be slightly better according to a significant percentage of endocrinologists. Familiarity with HCPs could represent much of the difference in access for patients.

More on ncarol.com

• HRC Fertility to Celebrate Grand Opening of New Beverly Hills Location During National Infertility Awareness Week
• AktieGo Publishes Editorial Feature Examining Decentralized Power Infrastructure and Hydrogen Energy Deployment
• Greg Wier Announces the Release of More Than Just Luck
• Nieuwe standaard in webdesign: Professionele website laten maken voor het MKB vanaf €249 door Websitepioniers
• Shipping Containers Are Powering the Next Generation of Bitcoin Mining Infrastructure

Despite significant excitement for physicians who are familiar with oral insulin there is significant excitement. There is an overall low level of familiarity with other oral T2D pipeline medications. Only 21% of HCPs are familiar with oral insulin, which is the highest percentage of familiarity among any clinical pipeline treatment.

Vivisum Partners surveyed Endocrinologists and HCPs about each oral type 2 diabetes pipeline therapy. The survey results specify their degree of excitement, "HCPs are evenly split between being excited (48%) vs. ambivalent (48%) towards Sotagliflozin", -said Vivisum's Oral Type 2 Diabetes strategist Patrick Brunell. He adds, this suggests that HCPs are interested in Sotagliflozin, but remain skeptical on how well it will perform in the market." Most Endocrinologists (80%) believe that Sotagliflozin will have about the same level of access as current diabetes medications.

Many of the metrics used in the report show that established treatments may have to get used to sharing larger portions of the Oral T2D marketplace. Relying on brand recognition may or may not be enough. Oral T2D Clinical Pipeline Analysis, https://vivisumpartners.com/reports/new-diabetes-medications-clinical-pipeline-analysis/, published in January 2023 by Vivisum Partners, examines each oral type 2 diabetes drug's strengths and weaknesses across six key clinical attributes:

• Access
• Dosing
• Efficacy
• Safety
• Support
• Tolerability

ABOUT VIVISUM PARTNERS, LLC

More on ncarol.com

• Art is Unfurling in Hillsborough
• Hypnotherapy Finder Announces Official US Wide Launch After Successful Soft Launch
• Melzi Job Coach Launches on iOS and Android: A Privacy-First AI Career Engine Built for Execution
• Training Lofts Launches $1,099 Unlimited Training Membership Featuring Semi-Private Coaching, Nutrition Support, and Recovery Services
• American Properties Realty, Inc. Leadership Attends NAHB International Builders' Show in Florida

Vivisum Partners, LLC is a market research agency providing strategic consulting around marketing and brand building. Vivisum provides facilitated discovery using market research methodologies and critical thinking processes. The actionable market research insights that Vivisum provides enable clients to shape their commercial strategies.